SANUWAVE Health Inc is committed to delivering innovative solutions in the field of regenerative medicine. With a focus on advanced wound care, the company aims to improve patient outcomes and quality of life. Their corporate philosophy is centered around pioneering technology, research, and clinical studies to develop safe and effective treatments for chronic and acute wounds. SANUWAVE Health Inc strives for collaboration with healthcare professionals and has a strong dedication to patient-centric care. Through their commitment to innovation, research, and customer satisfaction, SANUWAVE Health Inc continues to be a leader in the field of regenerative medicine.

SANUWAVE Health Inc is primarily present in the United States.

SANUWAVE Health Inc has achieved several significant milestones in its history. These include gaining regulatory approvals for its flagship product, dermaPACE®, a non-invasive shockwave device designed to promote healing of chronic wounds. The company has also expanded its market presence through strategic partnerships and distribution agreements, enabling broader access to its innovative medical technologies. SANUWAVE Health Inc has demonstrated its commitment to research and development, continually improving its product offerings and seeking new applications for its technology. The company's milestones reflect its dedication to advancing healthcare solutions and improving patient outcomes.

SANUWAVE Health Inc. is a renowned medical technology company specializing in the development and commercialization of non-invasive regenerative medicine solutions. With a strong focus on using innovative shockwave technology, SANUWAVE Health Inc. aims to improve patient healing and recovery in various medical fields. The company has a rich history and has been at the forefront of biomedical engineering advancements for over a decade. Having pioneered the use of shockwave therapy for wound management, SANUWAVE Health Inc.'s groundbreaking solutions have helped countless patients with acute and chronic conditions. Their commitment to research, development, and improving patient outcomes has solidified their position as a leader in the regenerative medicine industry.

The main competitors of SANUWAVE Health Inc in the market include companies like Acelity, Medtronic, Smith & Nephew, and Zimmer Biomet.

SANUWAVE Health Inc is primarily active in the healthcare industry.

The business model of SANUWAVE Health Inc focuses on the development and commercialization of advanced regenerative medicine products and devices primarily for the global wound care market. SANUWAVE aims to provide innovative solutions that promote the healing process, including the use of shockwave technology. By leveraging its expertise in the medical field, SANUWAVE aims to improve patient outcomes and reduce healthcare costs associated with chronic and acute wounds. Moreover, SANUWAVE Health Inc is committed to research, development, and strategic partnerships to advance its product portfolio and expand its reach in the healthcare industry.

SANUWAVE Health KGV ir 0.

SANUWAVE Health KUV ir 0,05.

AlleAktien kvalitātes vērtējums SANUWAVE Health ir 4/10.

gaidāmā SANUWAVE Health apgrozījums ir 240,19 milj. USD.

Pašlaik peļņa SANUWAVE Health nevar tikt aprēķināta.

SANUWAVE Health Inc is a leading company in the field of regenerative medicine, offering innovative therapy and diagnostic solutions for a variety of diseases. The company is headquartered in Suwanee, Georgia, USA and was founded in 2005. SANUWAVE's business model is based on the development and marketing of medical devices and procedures that enable rapid and effective healing of chronic and acute wounds, pain, and orthopedic conditions. The company focuses on the development of high-frequency shockwave therapies that stimulate the body's own regenerative processes and support healing. SANUWAVE's product portfolio currently includes two main areas, namely the orthopedic business and the wound care business. For the orthopedic field, SANUWAVE offers the OrthoPACE® device, which can treat painful musculoskeletal conditions. Shockwave therapy can be used for various orthopedic complaints such as tendon tears, muscle and ligament injuries, bone fractures, arthritis, back pain, and inflammation. For the wound care field, SANUWAVE offers the Pulsed Acoustic Cellular Expression (PACE) technology device, which allows for faster and more effective healing of chronic wounds such as diabetic foot ulcers, venous ulcers, or pressure ulcers. This technology is based on high-frequency shockwaves that create a type of "microtrauma" on the wound surface, stimulating the growth of new blood vessels and tissue. SANUWAVE follows a multi-stage distribution model and works closely with doctors, clinics, healthcare centers, and hospitals to provide its products and services. The company has a dedicated sales team that communicates with customers to educate them about the benefits of SANUWAVE products from a medical perspective. In addition, the company offers training and education to inform healthcare professionals about the application of shockwave therapies in practice. SANUWAVE also has a strong research and development department that constantly develops new products and applications to expand the product range and meet the needs of patients and medical professionals. In summary, SANUWAVE's business model is based on the development and marketing of innovative high-frequency shockwave therapies for orthopedic and wound care. By using PACE technology, the company offers products that enable fast and effective healing of acute and chronic wounds, inflammation, and pain. Thanks to a dedicated sales team and a strong research and development department, SANUWAVE is able to provide its customers with the latest and most advanced solutions in regenerative medicine.

SANUWAVE Health izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt SANUWAVE Health vai uzņēmums nedod dividendes.

SANUWAVE Health ISIN ir US80303D1072.

SANUWAVE Health simbols ir SNWV.

Pēdējo 12 mēnešu laikā SANUWAVE Health maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos SANUWAVE Health plāno maksāt dividendes 0 USD apmērā.

SANUWAVE Health pašreizējā dividendu rentabilitāte ir .

SANUWAVE Health maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

SANUWAVE Health pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

SANUWAVE Health tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu SANUWAVE Health apmērā 0 USD, kas tika izmaksāta 7.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.09.2024..

Pēdējās dividendes izmaksa notika 7.09.2024..

Gadā 2023, SANUWAVE Health izmaksāja 0 USD dividendes.

SANUWAVE Health dividendes tiek izmaksātas USD.